Parallel roles for dopamine in pathological gambling and psychostimulant addiction

Current Drug Abuse Reviews

Volumn 2, Issue 1, 2009, Pages 11-25

  Zack, Martin ^a,b   Poulos, Constantine X ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Addiction; Dopamine; Pathological gambling; Psychostimulant; Sensitization

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; METHYLPHENIDATE; MODAFINIL; NALMEFENE; NALTREXONE; OLANZAPINE; PIMOZIDE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; CENTRAL STIMULANT AGENT;

ALCOHOLISM; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; COMPULSION; DELUSION; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG DEPENDENCE; DRUG RESPONSE; GENETIC SUSCEPTIBILITY; HIGH RISK BEHAVIOR; HUMAN; MOTIVATION; NARCOLEPSY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROBIOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PHENOMENOLOGY; PRIORITY JOURNAL; SYMPTOM; ADDICTION; ANIMAL; ELECTROPHYSIOLOGY; METABOLISM; PATHOPHYSIOLOGY; REINFORCEMENT; REVIEW; REWARD;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; ELECTROPHYSIOLOGY; GAMBLING; HUMANS; MOTIVATION; RECEPTORS, DOPAMINE; REINFORCEMENT (PSYCHOLOGY); REWARD; SUBSTANCE-RELATED DISORDERS;

EID: 70349784673     PISSN: 18744737     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874473710902010011     Document Type: Article

References (182)

1. El-Guebaly N, Patten SB, Currie S, et al. Epidemiological associations between gambling behavior, substance use & mood and anxiety disorders. J Gambl Stud 2006; 22: 275-87.
2. Philippe F, Vallerand RJ. Prevalence rates of gambling problems in montreal, Canada: A Look at old adults and the role of passion. J Gambl Stud 2007 Mar 13; [Epub ahead of print].
3. Stucki S, Rihs-Middel M. Prevalence of adult problem and pathological gambling between 2000 and 2005: An Update. J Gambl Stud 2007 Jan 11; [Epub ahead of print].
4. Hodgins DC, Mansley C, Thygesen K. Risk factors for suicide ideation and attempts among pathological gamblers. Am J Addict 2006; 15: 303-10.
5. Morasco BJ, Pietrzak RH, Blanco C, Grant BF, Hasin D, Petry NM. Health problems and medical utilization associated with gambling disorders: results from the national epidemiologic survey on alcohol and related conditions. Psychosom Med 2006; 68: 976-84.
6. Petry NM, Stinson FS, Grant BF. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2005; 66: 564-74.
7. Toce-Gerstein M, Gerstein DR, Volberg RA. A hierarchy of gambling disorders in the community. Addiction 2003; 98:1661-72.
8. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (4th ed). Washington, DC: Author 1994.
9. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (4th ed-TR). Washington, DC: Author 2000.
10. Holden C. 'Behavioral' addictions: do they exist? Science 2001; 294(5544): 980-2.
11. Petry NM. Should the scope of addictive behaviors be broadened to include pathological gambling? Addiction 2006; 101 (Suppl 1): 152-60.
12. Potenza MN. Should addictive disorders include non-substance-related conditions? Addiction 2006; 101 (Suppl 1):142-51.
13. Baldo V, Cristofoletti M, Majori S, et al. Relationship between pathological gambling, alcoholism and drug addiction. Ann Ig 2006; 18(2): 147-53.
14. Sellman JD, Adamson S, Robertson P, Sullivan S, Coverdale J. Gambling in mild-moderate alcohol-dependent outpatients. Subst Use Misuse 2002; 37(2): 199-213.
15. Steinberg MA, Kosten TA, Rounsaville BJ. Cocaine abuse and pathological gambling. Am J Addict 1992; 1(2): 121-132.
16. Hall GW, Carriero NJ, Takushi RY, Montoya ID, Preston KL, Gorelick DA. Pathological gambling among cocaine-dependent outpatients. Am J Psychiatry 2000; 157:1127-33.
17. Brewer JA, Potenza MN. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 2008; 75(1): 63-75.
18. Iancu I, Lowengrub K, Dembinsky Y, Kotler M, Dannon PN. Pathological gambling: an update on neuropathophysiology and pharmacotherapy. CNS Drugs 2008; 22(2): 123-38.
19. Goudriaan AE, Oosterlaan J, de Beurs E, Van den Brink W. Pathological gambling: a comprehensive review of biobehavioral findings. Neurosci Biobehav Rev 2004; 28(2): 123-41.
20. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24(2): 97-129.
21. Blaszczynski A, Nower L. A pathways model of problem and pathological gambling. Addiction 2002; 97: 487-99.
22. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction 2000; 96(1): 103-14.
23. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 1998; 80(1): 1-27.
24. Fiorillo CD, Tobler PN, Schultz W. Discrete coding of reward probability and uncertainty by dopamine neurons. Science 2003; 299:1898-902.
25. Berns GS, McClure SM, Pagnoni G, Montague PR. Predictability modulates human brain response to reward. J Neurosci 2001; 21(8): 2793-8.
26. Delgado MR, Locke HM, Stenger VA, Fiez JA. Dorsal striatum responses to reward and punishment: effects of valence and magnitude manipulations. Cogn Affect Behav Neurosci 2003; 3(1): 27-38.
27. Elliott R, Newman JL, Longe OA, Deakin JF. Differential response patterns in the striatum and orbitofrontal cortex to financial reward in humans: a parametric functional magnetic resonance imaging study. J Neurosci 2003; 23(1): 303-7.
28. Galvan A, Hare TA, Davidson M, Spicer J, Glover G, Casey BJ. The role of ventral frontostriatal circuitry in reward-based learning in humans. J Neurosci 2005; 25(38): 8650-6.
29. Knutson B, Westdorp A, Kaiser E, Hommer D. FMRI visualization of brain activity during a monetary incentive delay task. Neuroimage 2000; 12(1): 20-7.
30. Knutson B, Fong GW, Adams CM, Varner JL, Hommer D. Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport 2001; 12(17): 3683-7.
31. Knutson B, Fong GW, Bennett SM, Adams CM, Hommer D. A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI. Neuroimage 2003: 18(2); 263-72.
32. Liu X, Powell DK, Wang H, Gold BT, Corbly CR, Joseph JE. Functional dissociation in frontal and striatal areas for processing of positive and negative reward information. J Neurosci 2007: 27(17); 4587-97.
33. Miyazaki K, Miyazaki KW, Matsumoto G. Different representation of forthcoming reward in nucleus accumbens and medial prefrontal cortex. Neuroreport 2004; 15(4): 721-6.
34. Knutson B, Bjork JM, Fong GW, Hommer D, Mattay VS, Weinberger DR. Amphetamine modulates human incentive processing. Neuron 2004; 43(2): 261-9.
35. Knutson B, Adcock RA. Remembrance of rewards past. Neuron 2005; 45(3): 331-2.
36. Reuter J, Raedler T, Rose M, Hand I, Glascher J, Buchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005; 8: 147-8.
37. Heffner TG, Hartman JA, Seiden LS. Feeding increases dopamine metabolism in the rat brain. Science 1980; 208(4448): 1168-70.
38. Young AM, Joseph MH, Gray JA. Increased dopamine release in vivo in nucleus accumbens and caudate nucleus of the rat during drinking: a microdialysis study. Neuroscience 1992; 48(4): 871-6.
39. Bailey CP, Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 2005; 5(1): 60-8.
40. Goudie AJ, Emmett-Oglesby MW. Psychoactive Drugs: Tolerance and Sensitization Humana Press, Clifton, NJ 1989.
41. Kalant H. Direct effects of ethanol on the nervous system. Fed Proc 1975; 34(10): 1930-41.
42. Perkins KA. Chronic tolerance to nicotine in humans and its relationship to tobacco dependence. Nicotine Tob Res 2002; 4(4): 405-22.
43. Haertzen CA. Addiction Research Center Inventory (ARCI): development of a general drug estimation scale. J Nerv Ment Dis 1965; 141: 300-7.
44. Hickey JE, Haertzen CA, Henningfield JE. Simulation of gambling responses on the addiction research center inventory. Addict Behav 1986; 11: 345-9.
45. Schenk S, Partridge B. Cocaine-seeking produced by experimenter-administered drug injections: dose-effect relationships in rats. Psychopharmacology 1999; 147: 285-90.
46. Zack M, Poulos CX. Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacology 2004; 29: 195-207.
47. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction 2001; 96: 103-14.
48. Shalev U, Grimm JW, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 2002; 54(1): 1-42.
49. Dagenbach D, Carr TH, Barnhardt TM. Inhibitory semantic priming of lexical decisions due to failure to retrieve weakly activated codes. J Exp Psychol Learn Mem Cogn 1990; 16: 328-40.
50. Konorski J. Integrative activity of the brain. University of Chicago Press: Chicago. 1967; pp. 531.
51. Kostowski W. Drug addiction as drive satisfaction ('antidrive') dysfunction. Acta Neurobiol Exp 2002; 62: 111-7.
52. Cannon CM, Palmiter RD. Reward without dopamine. J Neurosci 2003; 23(34): 10827-31.
53. Cooper SJ, Sweeney KF, Toates FM. Effects of spiperone on feeding performance in a food preference test. Psychopharmacology 1979; 63(3): 301-5.
54. Corrigall WA, Coen KM. Dopamine mechanisms play at best a small role in the nicotine discriminative stimulus. Pharmacol Biochem Behav 1994; 48(3): 817-20.
55. Ettenberg A, Pettit HO, Bloom FE, Koob GF. Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. Psychopharmacology 1982; 78(3): 204-9.
56. Laviolette SR, van der Kooy D. Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol Psychiatry 2003; 8(1): 50-9, 9.
57. Signs SA, Schechter MD. The role of dopamine and serotonin receptors in the mediation of the ethanol interoceptive cue. Pharmacol Biochem Behav 1988; 30(1): 55-64.
58. Callahan PM, Appel JB, Cunningham KA. Dopamine D1 and D2 mediation of the discriminative stimulus properties of damphetamine and cocaine. Psychopharmacology 1991; 103(1): 50-5.
59. Johanson CE, Kandel DA, Bonese K. The effects of perphenazine on self-administration behavior. Pharmacol Biochem Behav 1976; 4(4): 427-33.
60. Smith FL, St John C, Yang TF, Lyness WH. Role of specific dopamine receptor subtypes in amphetamine discrimination. Psychopharmacology 1989; 97(4): 501-6.
61. Woolverton WL. Effects of a D1 and a D2 dopamine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol Biochem Behav 1986; 24(3): 531-5.
62. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 2006; 30(2): 215-38.
63. Zack M, Poulos CX. A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. Neuropsychopharmacology 2007; 32(8): 1678-86.
64. Meyer G, Schwertfeger J, Exton MS, et al. Neuroendocrine response to casino gambling in problem gamblers. Psychoneuroendocrinology 2004; 29(10): 1272-80.
65. Volkow ND, Wang GJ, Fowler JS, et al. Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology 2003; 166(3):264-70.
66. Scott-Railton J, Vezina P. Sensitization-like neuroplasticity in rats chronically exposed to intermittent reinforcement. Society Neurosci Abstracts, Press Book Part 2. 2006; p. 122.
67. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology 2007; 191(3): 391-431.
68. Robbins TW, Everitt BJ. A role for mesencephalic dopamine in activation: commentary on Berridge (2006). Psychopharmacology 2007; 191(3): 433-7.
69. Panksepp J. Affective Neuroscience: The Foundations of Human and Animal Emotions. Oxford University Press: New York 1999.
70. Plutchik R, Kellerman H, Eds. The measurement of emotions emotion: Theory, research and experience. Academic Press, Orlando, FL Vol. 4; 1989.
71. Berridge CW. Neural substrates of psychostimulant-induced arousal. Neuropsychopharmacology 2006; 31(11): 2332-40.
72. Pallanti S, Bernardi S, Quercioli L, DeCaria C, Hollander E. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo. CNS Spectr 2006; 11(12): 956-64.
73. Buydens-Branchey L, Branchey M, Fergeson P, Hudson J, McKernin C. The meta-chlorophenylpiperazine challenge test in cocaine addicts: hormonal and psychological responses. Biol Psychiatry 1997; 41(11):1071-86.
74. Bagdy G, Szemeredi K, Hill JL, Murphy DL. The serotonin agonist, M-chlorophenylpiperazine, markedly increases levels of plasma catecholamines in the conscious rat. Neuropharmacology 1988; 27(10): 975-80.
75. Eriksson E, Engberg G, Bing O, Nissbrandt H. Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 1999; 20(3): 287-96.
76. Volkow ND, Wang GJ, Fowler JS, et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 1999; 291(1): 409-15.
77. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49(2): 81-96.
78. Brauer LH, de Wit H. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psychiatry 1996; 39: 26-32.
79. Romach MK, Glue P, Kampman K, et al. Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry 1999; 56(12): 1101-6.
80. Thompson B, Leonard KC, Brudzynski SM. Amphetamine-induced 50 kHz calls from rat nucleus accumbens: a quantitative mapping study and acoustic analysis. Behav Brain Res 2006; 168(1): 64-73.
81. Adinoff B. Neurobiologic processes in drug reward and addiction. Harv Rev Psychiatry 2004; 12(6): 305-20.
82. Grace AA. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 2000; 95 (Suppl 2): S119-28.
83. Redish AD. Addiction as a computational process gone awry. Science 2004; 306 (5703):1944-7.
84. Redish AD, Jensen S, Johnson A, Kurth-Nelson Z. Reconciling reinforcement learning models with behavioral extinction and renewal: implications for addiction, relapse, and problem gambling. Psychol Rev 2007; 114(3): 784-805.
85. Rescorla RA, Wagner AR. A theory of Pavlovian conditioning: Variations in the effectiveness of reinforcement and nonreinforcement, Classical Conditioning II. In: Black AH, Prokasy WF, Eds. Appleton-Century-Crofts 1972; pp. 64-99.
86. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 1995; 5(3): 121-41.
87. Noble EP. Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. Eur Psychiatry 2000; 15(2): 79-89.
88. Enggasser JL, de Wit H. Haloperidol reduces stimulant and reinforcing effects of ethanol in social drinkers. Alcohol Clin Exp Res 2001; 25: 1448-56.
89. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57-73.
90. Wachtel SR, Ortengren A, de Wit H. The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend 2002; 68: 23-33.
91. Volkow ND, Wang GJ, Fowler JS, et al. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 1999; 156(9): 1440-3.
92. Volkow ND, Wang GJ, Fowler JS, et al. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 2002; 46: 79-82.
93. Brauer LH, de Wit H. Role of dopamine in d-amphetamine-induced euphoria in normal, healthy volunteers. Exp Clin Psychopharmacol 1995; 3: 371-81.
94. Brauer LH, De Wit H. High dose pimozide does not block amphetamine-induced euphoria in normal volunteers. Pharmacol Biochem Behav 1997; 56: 265-72.
95. Shi WX, Smith PL, Pun CL, Millet B, Bunney BS. D1-D2 interaction in feedback control of midbrain dopamine neurons. J Neurosci 1997; 17: 7988-94.
96. Pehek EA. Comparison of effects of haloperidol administration on amphetamine-stimulated dopamine release in the rat medial prefrontal cortex and dorsal striatum. J Pharmacol Exp Ther 1999; 289: 14-23.
97. Self DW, Barnhart WJ, Lehman DA, Nestler EJ. Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 1996; 271 (5255): 1586-9.
98. Self DW. Neural substrates of drug craving and relapse in drug addiction. Ann Med 1998; 30(4): 379-89.
99. Chausmer AL, Smith BJ, Kelly RY, Griffiths RR. Cocaine-like subjective effects of nicotine are not blocked by the D1 selective antagonist ecopipam (SCH 39166). Behav Pharmacol 2003; 14(2):111-20.
100. McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry 2008; 69(3): 433-40.
101. Fong T, Kalechstein A, Bernhard B, Rosenthal R, Rugle L. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav 2008; 89(3): 298-303.
102. Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 2004; 161(9):1620-5.
103. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124(1-2): 57-73.
104. Zack M, Poulos CX. Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high versus low impulsivity. J Psychopharmacology (in press).
105. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30: 205-11.
106. Wigal SB, Biederman J, Swanson JM, Yang R, Greenhill LL. Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: pooled analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion J Clin Psychiatry 2006; 8(6): 352-60.
107. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 2004; 55: 1031-40.
108. Dackis CA, Lynch KG, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003; 70(1): 29-37.
109. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2007; [Epub ahead of print].
110. Minzenberg MJ, Carter CS. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2007 Aug 22; [Epub ahead of print].
111. Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol 2007; 568(1-3): 112-23. [Epub ahead of print].
112. Korotkova TM, Klyuch BP, Ponomarenko AA, Lin JS, Haas HL, Sergeeva OA. Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors. Neuropharmacology 2007; 52: 626-33.
113. Logan GD, Schachar RJ, Tannock R. Impulsivity and inhibitory control. Psychol Sci 1997; 8: 60-4.
114. Bechara A. Risky business: emotion, decision-making, and addiction. J Gambl Stud 2003; 19: 23-51.
115. Eysenck SBG, Pearson PR, Easting G, Allsopp JF. Age norms for impulsiveness, venturesomeness, and empathy in adults. Person Individ Diff 1985; 6: 613-9.
116. Petry NM. Pathological gamblers, with and without substance use disorders, discount delayed rewards at high rates. J Abnorm Psychol 2001; 110: 482-7.
117. Aronen ET, Vuontela V, Steenari MR, Salmi J, Carlson S. Working memory, psychiatric symptoms, and academic performance at school. Neurobiol Learn Mem 2005; 83(1): 33-42.
118. Dretsch MN, Tipples J. Working memory involved in predicting future outcomes based on past experiences. Brain Cogn 2007; [Epub ahead of print].
119. Finn PR, Justus A, Mazas C, Steinmetz JE. Working memory, executive processes and the effects of alcohol on Go/No-Go learning: testing a model of behavioral regulation and impulsivity. Psychopharmacology 1999; 146(4): 465-72.
120. Frank MJ, O'Reilly RC. A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol. Behav Neurosci 2006; 120: 497-517.
121. Cools R, Sheridan M, Jacobs E, et al. Impulsive personality predicts dopamine-dependent changes in frontostriatal activity during component processes of working memory. J Neurosci 2007; 27: 5506-14.
122. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 2004; 74(1):1-58.
123. Goudriaan AE, Oosterlaan J, De Beurs E, Van Den Brink W. The role of self-reported impulsivity and reward sensitivity versus neurocognitive measures of disinhibition and decision-making in the prediction of relapse in pathological gamblers. Psychol Med 2008; 38(1):41-50.
124. Alessi SM, Petry NM. Pathological gambling severity is associated with impulsivity in a delay discounting procedure. Behav Processes 2003; 64 (3): 345-54.
125. Franken IH, van Strien JW, Nijs I, Muris P. Impulsivity is associated with behavioral decision-making deficits. Psychiatry Res 2008; 158(2): 155-63.
126. Beaudoin CM, Cox BJ. Characteristics of problem gambling in a Canadian context: A preliminary study using a DSM-IV-based questionnaire. Can J Psychiatry 1999; 44: 483-7.
127. Steel Z, Blaszczynski A Impulsivity, personality disorders and pathological gambling severity. Addiction 1998; 93: 895-905.
128. Grosset KA, Macphee G, Pal G, et al. Problematic gambling on dopamine agonists: Not such a rarity. Mov Disord 2006; 21(12): 2206-8.
129. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006; 66(11): 1750-2.
130. Singh A, Kandimala G, Dewey RB Jr, O'suilleabhain P. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci 2007; [Epub ahead of print].
131. Lukas SE, Sholar M, Lundahl LH, et al. Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers. Psychopharmacology 1996; 125(4): 346-54.
132. Riccardi P, Zald D, Li R, et al. Sex differences in amphetamine-induced displacement of [(18) F] fallypride in striatal and extrastriatal regions: a PET study. Am J Psychiatry 2006; 163(9): 1639-41.
133. Stamey W, Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist 2008; 14(2): 89-99.
134. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63(7): 969-73.
135. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005; 65(10): 1570-4.
136. Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007; 64(8): 1089-96.
137. Kaasinen V, Ruottinen HM, Nagren K, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C] N-methylspiperone. J Nucl Med 2000; 41(1): 65-70.
138. Scherfler C, Khan NL, Pavese N, et al. Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations. Mov Disord 2006; 21(6): 783-8.
139. Siemiatkowski M, Maciejak P, Wislowska A, et al. Neophobia and cortical and subcortical binding of the dopamine D2 receptor antagonist [3H]-raclopride. Life Sci 2004; 76(7): 753-61.
140. Kaasinen V, Någren K, Hietala J, Farde L, Rinne JO. Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. Am J Psychiatry 2001; 158(2): 308-11.
141. Volkow ND, Wang GJ, Begleiter H, et al. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Arch Gen Psychiatry 2006; 63(9): 999-1008.
142. Le Moal M. Addiction: a disease like no other? Rev Prat 2003; 53(12): 1294-8.
143. Vezina P, Pierre PJ, Lorrain DS. The effect of previous exposure to amphetamine on drug-induced locomotion and self-administration of a low dose of the drug. Psychopharmacology 1999; 147(2): 125-34.
144. Fletcher PJ, Tenn CC, Rizos Z, Lovic V, Kapur S. Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology 2005; 183 (2): 190-200.
145. Tenn CC, Kapur S, Fletcher PJ. Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. Psychopharmacology 2005; 180(2): 366-76.
146. Featherstone RE, Kapur S, Fletcher PJ. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(8): 1556-71.
147. Glenthoj BY, Hemmingsen R. Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21(1): 23-46.
148. Myin-Germeys I, Delespaul P, van Os J. Behavioural sensitization to daily life stress in psychosis. Psychol Med 2005; 35(5): 733-41.
149. Ujike H. Stimulant-induced psychosis and schizophrenia: the role of sensitization. Curr Psychiatry Rep 2002; 4(3): 177-84.
150. Boileau I, Dagher A, Leyton M, et al. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 2006; 63(12): 1386-95.
151. Bergh C, Eklund T, Sodersten P, Nordin C. Altered dopamine function in pathological gambling. Psychol Med 1997; 27(2): 473-5.
152. Nordin C, Sjodin I. CSF cholecystokinin, gamma-aminobutyric acid and neuropeptide Y in pathological gamblers and healthy controls. J Neural Transm 2007; 114(4): 499-503.
153. Goudriaan AE, Oosterlaan J, de Beurs E, van den Brink W. Decision making in pathological gambling: a comparison between pathological gamblers, alcohol dependents, persons with Tourette syndrome, and normal controls. Brain Res Cogn Brain Res 2005; 23(1): 137-51.
154. Goudriaan AE, Oosterlaan J, de Beurs E, van den Brink W. Neurocognitive functions in pathological gambling: a comparison with alcohol dependence, Tourette syndrome and normal controls. Addiction 2006; 101(4): 534-47.
155. Leiserson V, Pihl RO. Reward-sensitivity, inhibition of reward-seeking, and dorsolateral prefrontal working memory function in problem gamblers not in treatment. J Gambl Stud 2007; 23(4): 435-55.
156. Stojanov W, Karayanidis F, Johnston P, Bailey A, Carr V, Schall U. Disrupted sensory gating in pathological gambling. Biol Psychiatry 2003; 54(4): 474-84.
157. Reynolds GP. Neurotransmitter systems in schizophrenia. Int Rev Neurobiol 1995; 38: 305-39.
158. Morrison PD, Murray RM. Schizophrenia. Curr Biol 2005; 15(24): R980-4.
159. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006; 10(4): 515-31.
160. Sato M. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann N Y Acad Sci 1992; 654: 160-70.
161. Yin K, Goto K, Ikemoto S. The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence. Ann N Y Acad Sci 2004; 1025: 296-306.
162. Delfabbro P. The stubborn logic of regular gamblers: obstacles and dilemmas in cognitive gambling research. J Gambl Stud 2004; 20(1): 1-21.
163. Joukhador J, Blaszczynski A, Maccallum F. Superstitious beliefs in gambling among problem and non-problem gamblers: preliminary data. J Gambl Stud 2004; 20(2): 171-80.
164. Ladouceur R. Perceptions among pathological and nonpathological gamblers. Addict Behav 2004; 29(3): 555-65.
165. Toneatto T, Millar G. Assessing and treating problem gambling: empirical status and promising trends. Clinical Research Department. Can J Psychiatry 2004; 49(8): 517-25.
166. Toneatto T. Cognitive psychopathology of problem gambling. Subst Use Misuse 1999; 34(11): 1593-604.
167. Toneatto T, Blitz-Miller T, Calderwood K, Dragonetti R, Tsanos A. Cognitive distortions in heavy gambling. J Gambl Stud 1997; 13(3): 253-66.
168. Schneider, K. Clinical Psychopathology New York: Grune and Stratton 1959.
169. Echeburua E, Fernandez-Montalvo J. Psychological treatment of slot-machine pathological gambling: new perspectives. J Gambl Stud 2005; 21(1): 21-6.
170. Tavares H, Zilberman ML, el-Guebaly N. Are there cognitive and behavioural approaches specific to the treatment of pathological gambling? Can J Psychiatry 2003; 48(1): 22-7.
171. Grant JE, Mancebo MC, Pinto A, Eisen JL, Rasmussen SA. Impulse control disorders in adults with obsessive compulsive disorder. J Psychiatr Res 2006; 40(6): 494-501.
172. Eilam D, Szechtman H. Psychostimulant-induced behavior as an animal model of obsessive-compulsive disorder: an ethological approach to the form of compulsive rituals. CNS Spectr 2005; 10(3): 191-202.
173. Zadicario P, Ronen S, Eilam D. Modulation of quinpirole-induced compulsive-like behavior in rats by environmental changes: implications for OCD rituals and for exploration and navigation. BMC Neurosci 2007; 8: 23.
174. Lader M. Antiparkinsonian medication and pathological gambling. CNS Drugs 2008; 22(5): 407-16.
175. Heinz A, Mann K, Weinberger DR, Goldman D. Serotonergic dysfunction, negative mood states, and response to alcohol. Alcohol Clin Exp Res 2001; 25(4): 487-95.
176. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49(11): 914-21.
177. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006; 163(2): 303-12.
178. Hollander E, Kaplan A, Pallanti S. Pharmacological treatments. In: Grant JE, Potenza MN, Eds. Pathological gambling: A clinical guide to treatment. Washington, DC: American Psychiatric Pub. 2004; pp. 189-205.
179. Jayaram-Lindstrom N, Wennberg P, Hurd YL, Franck J. Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol 2004; 24(6): 665-9.
180. Comings DE, Gade-Andavolu R, Gonzalez N, et al. The additive effect of neurotransmitter genes in pathological gambling. Clin Genet 2001; 60(2): 107-16.
181. Larson EB, Carroll ME. Wheel running as a predictor of cocaine self-administration and reinstatement in female rats. Pharmacol Biochem Behav 2005; 82(3): 590-600.
182. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004; 9(6): 557-69.